Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- CAA definition and pathological diagnosis
- Additional pathological aspects
- CAA subtypes
- Sporadic CAA
- Pathophysiology of vascular deposition of Aβ
- Main clinical presentation: lobar ICH
- Non-ICH clinical presentations
- Diagnostic challenges
- CAA related sporadic ICH (1)
- CAA related sporadic ICH (2)
- Mechanistic challenges
- Novel approaches to improve understanding of CAA mechanisms
- Therapeutic challenges
- Thank you for listening
Topics Covered
- Cerebral Amyloid Angiopathy Pathological (CAA) diagnosis
- CAA subtypes
- Sporadic CAA
- Lobar ICH and its clinical presentation
- Diagnostic challenges
- CAA-related sporadic ICH
- Mechanistic challenges
- Therapeutic challenges
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Baron, J. (2023, May 31). Cerebral amyloid angiopathy (CAA): a clinical disorder [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/NNDX8946.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jean-Claude Baron has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Cerebral Amyloid Angiopathy (CAA)
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Jean-Claude Barron.
I'm a Neurologist
with special interest
in stroke medicine,
and as well as
neuroscientist and
i'm coordinating this
series of talks on
Cerebral Amyloid Angiopathy, CAA
and this is an introductory
talk where I will
just briefly go over the
main aspects of CAA,
and everything I will say,
will be developed and
expanded within each
of the 16 specific
talks of this series.
What is CAA?
0:42
CAA is defined pathologically
by an abnormal deposition
of beta amyloid many
A-Beta-40 in the media
of the small and
medium size cortical and
leptomeningeal arteries.
This is very important
to understand that
CAA is a disease of the
surface of the brain,
the meninges, and the surface
of the cortex mainly.
Diagnosis is made
pathologically because
the amyloid binds Congo red
as shown on the bottom left,
and is fluorescent with
Thioflevin S. However,
to make a specific
diagnosis of CAA,
it is highly recommended to do
immunohistochemistry
using a-Beta antibodies
as shown on the bottom right.